A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway

NCT#: & Link

NCT05578092

NCT QR Code

Available as of:

October 14, 2024

Contract:

Optimal

Indication Category:

Solid Tumors, NSCLC

Study Sponsor:

Mirati Therapeutics

Protocol #:

0902-001

Title:

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway

Highlight Details:

NSCLC previously treated with KRAS G12C inhibitor Solid Tumor not previously treated with KRAS G12C inhibitor

This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.

Biomarkers:

KRAS G12C

Indication:

NSCLC, Other Solid Tumors

Phase:

1/2

Treatment Line:

Study Drug/Test Compound:

MRTX0902 + Adagrasib

Notes

Recruitment Status:

Just In Time

Participating Institution:

Salinas Valley Health

Salinas Valley Health Clinical Research Program:

Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, research@salinasvalleyhealth.com